Baird R W lowered shares of Bio-Techne (NASDAQ:TECH – Free Report) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports. Several other research ...

Fintel reports that on February 19, 2025, Baird downgraded their outlook for Bio-Techne (NasdaqGS:TECH) from Outperform to ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Bio-Techne (TECH) announced the launch of an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology ...

Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral ...

Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance ...

Baird analyst Catherine Ramsey Schulte downgraded Bio-Techne (TECH) to Neutral from Outperform with a price target of $68, down from $88. The ...

Bio-Techne (NASDAQ:TECH – Get Free Report) was downgraded by stock analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, Ratings reports. They ...

Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a leading provider of life sciences solutions ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. BofA upgraded ...